Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Judy Costas"'
Autor:
B. Douglas Smith, David Bearss, Stephen P. Anthony, Kathryn Kolibaba, Judy Costas, Gil D. Fine, Mark Frattini, Daniel J. Lee, Joshua F. Zeidner
Supplementary Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9495f22805f8fae8c9d8f543113901
https://doi.org/10.1158/1078-0432.22478183
https://doi.org/10.1158/1078-0432.22478183
Autor:
B. Douglas Smith, David Bearss, Stephen P. Anthony, Kathryn Kolibaba, Judy Costas, Gil D. Fine, Mark Frattini, Daniel J. Lee, Joshua F. Zeidner
Purpose:Alvocidib is a cyclin-dependent kinase 9 inhibitor leading to downregulation of the antiapoptotic BCL-2 family member, MCL-1. Alvocidib has shown clinical activity in a timed sequential regimen with cytarabine and mitoxantrone in relapsed/ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28623428ff21a2d060de211f7b20a17b
https://doi.org/10.1158/1078-0432.c.6529880
https://doi.org/10.1158/1078-0432.c.6529880
Autor:
Kathryn Kolibaba, Daniel J. Lee, Joshua F. Zeidner, Stephen P. Anthony, David J. Bearss, Judy Costas, Gil Fine, Mark G. Frattini, B. Douglas Smith
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(1)
Purpose: Alvocidib is a cyclin-dependent kinase 9 inhibitor leading to downregulation of the antiapoptotic BCL-2 family member, MCL-1. Alvocidib has shown clinical activity in a timed sequential regimen with cytarabine and mitoxantrone in relapsed/re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eaac367faced7aadeed4bb2d0f4443d
https://pubmed.ncbi.nlm.nih.gov/32998965
https://pubmed.ncbi.nlm.nih.gov/32998965
